Table 1.
Patient characteristics
| Patient characteristics | Overall cohort (n = 370) |
|---|---|
| Age, median (min-max) | 68.5 (32.0-87.0) |
| Sex, n (%) | |
| Male | 199 (53.8%) |
| Female | 171 (46.2%) |
| ECOG performance status, n = 321, n (%) | |
| 0 | 180 (56.1%) |
| 1 | 120 (37.4%) |
| 2 | 21 (6.5%) |
| Body mass index (kg/m2), n = 367, median (IQR) | 29.5 (26.2-33.7) |
| pTNM Stage, n (%) | |
| 0 | 7 (1.9%) |
| I | 100 (27.1%) |
| II | 65 (17.6%) |
| III | 197 (53.4%) |
| Resection margin, n = 369, n (%) | |
| R0 | 359 (97.3%) |
| R1 | 10 (2.7%) |
| Pathological subtype, n = 370, n (%) | |
| Intestinal | 109 (29.5%) |
| Pancreatobiliary | 150 (40.5%) |
| Mixed/Undetermined | 32 (8.6%)/79 (21.4%) |
| Not determined | 79 (21.4%) |
| Tumor grade, n = 370, n (%) | |
| Low | 103 (27.8%) |
| Intermediate | 166 (44.9%) |
| High | 44 (11.9%) |
| Undetermined | 57 (15.4%) |
| MMR status, n = 134, n (%) | |
| MSI-high/dMMR | 13 (9.7%) |
| MSS/pMMR | 121 (90.3%) |
| Adjuvant chemotherapy, n = 370, n (%) | |
| No | 144 (38.9%) |
| Yes | 226 (61.1%) |
| Single-agent | 73 (32.3%) |
| Doublet/triplet | 153 (67.7%) |
dMMR, deficient mismatch repair; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; MSI, microsatellite instability; MSS, microsatellite stability; pMMR, proficient MMR; TNM, tumor–node–metastasis.